Skip to main content

CORRECTION article

Front. Oncol., 15 August 2022
Sec. Cancer Immunity and Immunotherapy
Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.974476

Corrigendum: Single-cell technologies to decipher the immune microenvironment in myeloid neoplasms: Perspectives and opportunities

Chiara Caprioli,,Chiara Caprioli1,2,3Iman Nazari,Iman Nazari1,2Sara Milovanovic,Sara Milovanovic1,2Pier Giuseppe Pelicci,*Pier Giuseppe Pelicci1,2*
  • 1Department of Experimental Oncology, IRCCS Istituto Europeo di Oncologia, Milan, Italy
  • 2Scuola Europea di Medicina Molecolare (SEMM) European School of Molecular Medicine, Milan, Italy
  • 3Hematology and Bone Marrow Transplant Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy

A Corrigendum on
Single-cell technologies to decipher the immune microenvironment in myeloid neoplasms: Perspectives and opportunities

by Caprioli C, Nazari I, Milovanovic S and Pelicci PG (2022). Front. Oncol. 11:796477. doi: 10.3389/fonc.2021.796477

In the published article, there was an error in affiliation Number 1. Instead of “Department of Experimental Oncology, Istituto Europeo di Oncologia, Milan, Italy”, it should be “Department of Experimental Oncology, IRCCS Istituto Europeo di Oncologia, Milan, Italy”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: single-cell sequencing, myelodysplastic syndromes, acute myeloid leukemia, clonal hematopoiesis, immunotherapies, immune microenvironment

Citation: Caprioli C, Nazari I, Milovanovic S and Pelicci PG (2022) Corrigendum: Single-cell technologies to decipher the immune microenvironment in myeloid neoplasms: Perspectives and opportunities. Front. Oncol. 12:974476. doi: 10.3389/fonc.2022.974476

Received: 21 June 2022; Accepted: 01 August 2022;
Published: 15 August 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Caprioli, Nazari, Milovanovic and Pelicci. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Pier Giuseppe Pelicci, piergiuseppe.pelicci@ieo.it

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.